Active Ingredient(s):Tisotumab Vedotin-tftv FDA Approved: * September 20, 2021 Pharm Company: *SEAGEN Category:Cancer
Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. It is a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division.
Tisotumab vedotin was approved for medical use in the United States in September 2021. It is administered by infusion into a vein every 3 weeks.
* May have multiple approval dates, manufacturers, or labelers. 3 Discussions
Tivdak 40 mg/4ml Intravenous Injection, Powder, for Solution